Call: +7 771 977 66 65, +7 705 421 2277
Sign in or Register
My basket

Astana Biomed Group, an authorized Abcam distributor in Central Asia

Abiomed homepage

  • Categories
    Signal Transduction
    Cancer
    Epigenetics and Nuclear Signaling
    Immunology
    Cell Biology
    Cardiovascular
    Neuroscience
    Tags & Cell Markers
    Kits/ Lysates/ Other
    Developmental Biology
    Microbiology
    Biochemicals
    Secondary antibodies
    Isotype/Loading Controls
    Antibody Arrays
  • About us
  • Partners
  • Contact
    Address

    Saryarka 32, 18, 010000, Astana city, Kazakhstan

    Telephone +7 771 977 66 65, +7 705 421 2277

    Email

    laboratory@ctlab.kz, orders@abiomed.kz

Back to category

Phagocytosis Assay Kit (Red Zymosan) (ab234054)

Phagocytosis Assay Kit (Red Zymosan) (ab234054)
  • ChIP - Anti-Histone H3 antibody - Nuclear Loading Control and ChIP Grade (ab1791)
  • ChIP - Anti-Histone H3 antibody - Nuclear Loading Control and ChIP Grade (ab1791)
  • ChIP - Anti-Histone H3 antibody - Nuclear Loading Control and ChIP Grade (ab1791)

Key features and details

  • Detection method: Fluorescent
  • Platform: Microplate reader, Fluor. microscope, Flow cyt.
  • Sample type: Adherent cells, Suspension cells

You may also be interested in

Product image
Anti-c20orf72 antibody (ab224169)
Anti-LIFR antibody [MM0455-9B23] (ab89792)
Product image
Anti-SOCS3 antibody [OTI3D3] (ab236519)
Product image
Recombinant Human CD172 gamma protein (denatured) (ab180289)

Overview

  • Product name

    Phagocytosis Assay Kit (Red Zymosan)
    See all Phagocytosis kits
  • Detection method

    Fluorescent
  • Sample type

    Adherent cells, Suspension cells
  • Species reactivity

    Reacts with: Mammals, Other species
  • Product overview

    Phagocytosis Assay Kit ab234054 uses Zymosan particles which have been pre-labeled with a red dye.


    The assay can be used for the rapid and accurate detection and quantification of in vitro phagocytosis by fluorescent microscope, spectrophotometer or flow cytometry. It provides a robust screening system for activators and/or inhibitors of phagocytosis and Toll-like receptors ligands (TLR).


    The Zymosan particles used in the phagocytosis assay protocol are labeled for fluorescence at Ex/Em 540/570 nm.


    Phagocytosis assay protocol summary:
    - add Zymosan to cells and incubate for 2-3 hrs
    - harvest cells and resuspend pellet in phagocytosis assay buffer, repeat three times to wash off any remaining Zymosan which is not inside cells
    - analyze cells with flow cytometer, fluorescent microscope, or microplate reader

  • Notes

    In mammals, phagocytosis by phagocytes (e.g., macrophages, dendritic cells, and neutrophils) is essential for a variety of biological events. Phagocytosis comprises a series of events, starting with the binding and recognition of particles by cell surface receptors, followed by the formation of actin-rich membrane extensions around the particle.  

    Zymosan (Saccharomyces cerevisiae) is prepared from yeast cell wall and consists of protein-carbohydrate complexes.  Zymosan is a commonly used pathogen in phagocytosis assays.

  • Platform

    Microplate reader, Fluor. microscope, Flow cyt.

Properties

  • Storage instructions

    Store at +4°C. Please refer to protocols.
  • Components 100 tests
    Phagocytosis Assay Buffer 2 x 100ml
    Buffer Additive 2 x 1ml
    Red Zymosan (Cy3) 1 x 600µl
    10X Quenching Solution 1 x 500µl

Images

  • Inhibition of phagocytosis.
    Inhibition of phagocytosis.

    J774 macrophages were seeded overnight at 5 x 105 of viable cells/well. The next day the cells were pretreated with 20 µM Cytochalasin D for 1 h at 37ºC prior to addition of 5 µl of Zymosan particles. Phagocytosis was conducted for 2 hours and the amount of engulfed Zymosan was determined as described in the Assay Protocol.

    Panel A and B: images of non-treated cells. Panel C and D: treatment with Cytochalasin D.

  • Flow cytometry plot.
    Flow cytometry plot.

    J774 macrophages were seeded overnight at 5 x 105 of viable cells/well. The next day the cells were pretreated with 20 µM Cytochalasin D for 1 h at 37ºC prior to addition of 5 µl of Zymosan particles. Phagocytosis was conducted for 2 hours and the amount of engulfed Zymosan was determined as described in the Assay Protocol.

    Black line: untreated control cells; red line: macrophages with engulfed Zymosan particles; blue line: inhibition of phagocytosis by Cytochalasin D.

  • Zymosan Standard curve.
    Zymosan Standard curve.

    J774 macrophages were seeded overnight at 5 x 105 of viable cells/well. The next day the cells were pretreated with 20 µM Cytochalasin D for 1 h at 37ºC prior to addition of 5 µl of Zymosan particles. Phagocytosis was conducted for 2 hours and the amount of engulfed Zymosan was determined as described in the Assay Protocol.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Alternative products to Phagocytosis Assay Kit (Red Zymosan) (ab234054)

  •  
  • Product image

    Phagocytosis Assay Kit (Red E. coli) (ab235901)

    Applications:

  •  
  • Product image

    Phagocytosis Assay Kit (Zymosan Substrate) (ab211156)

    Applications:

  •  
  • Product image

    Phagocytosis Assay Kit (Green Zymosan) (ab234053)

    Applications:

  •  
  • Product image

    Phagocytosis Assay Kit (Green E.coli) (ab235900)

    Applications:

Clear all

Recently viewed products

  •  
  • Product image

    Anti-MyoD1 antibody [EPR6653-131] (ab133627)

  •  
  • Product image

    Anti-IL-15 antibody [EPR1542Y] (ab134177)

  •  
  • Product image

    Anti-VEGFC antibody [mAbcam 63221] (ab63221)

  •  
  • Product image

    Anti-STK3/MST-2 (phospho T180) + MSP/MST1 (phospho T183) antibody (ab79199)

  •  
  • Product image

    PE/Cy7® Anti-Interferon gamma antibody [4S.B3] (ab234208)

  •  
  • Product image

    Anti-CD75 antibody - BSA and Azide free (Capture) (ab275282)

Get resources and offers direct to your inbox Sign up
© 2021 Astana Biomed Group LLP. All rights reserved.